Skip to content

Heart Valve Prosthesis-Patient Mismatch

Impact of Prosthesis-Patient Mismatch on Clinical Outcomes After Mitral Valve Replacement

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00629902
Enrollment
100
Registered
2008-03-06
Start date
2008-02-29
Completion date
2008-05-31
Last updated
2008-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Valve Diseases

Keywords

Heart valve prosthesis

Brief summary

The purpose of this study is to determine the frequency of prosthesis-patient mismatch after mitral valve replacement and its effect on clinical outcomes.

Detailed description

Mitral valve replacement (MVR) is associated with higher short and long term mortality than aortic valve replacement or mitral valve repair. The suboptimal results of MVR underline the importance of identifying and preventing prosthesis- patient mismatch. The effective orifice area (EOA) of prosthetic valves used for MVR is often too small in relation to body size, thus causing a mismatch between valve EOA and transvalvular flow. As a consequence, normally functioning mitral prostheses often have relatively high gradients that are similar to those found in patients with mild to moderate mitral stenosis. Residual pressure gradients across mitral prostheses delay the regression of left atrial and pulmonary arterial hypertension. Pulmonary hypertension may cause rightsided failure and is an important risk factor for morbidity and mortality in patients with cardiovascular diseases. However data about the frequency of prosthesis-patient mismatch after mitral valve replacement and its effect on clinical outcome is inconclusive. Predetermined outcomes will be evaluated in the clinical course of this condition.

Interventions

None listed

Sponsors

Florence Nightingale Hospital, Istanbul
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients \> 18 years with a clinical condition of mitral valve prosthesis

Exclusion criteria

* Evidence of prosthesis valve dysfunction (dehisence, endocarditis or thrombus of prosthetic mitral valve) * Concomitant aortic valve prosthesis and tricuspid valve prosthesis * Presence of \> +2 aortic valve regurgitation and/or mild aortic stenosis * Prosthetic mitral valve replacement operation \< 6 months * Left ventricular ejection fraction \< 50% * Chronic obstructive pulmonary disease * Concomitant hypertrophic cardiomyopathy, atrial septal defect * Patients with poor ehocardiographic window

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026